Yonsei University has divulged protein kinase inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified EGFR (HER1; erbB1) wild-type and/or mutant inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer (NSCLC).

Deciphera Pharmaceuticals LLC has synthesized heterocyclic compounds acting as eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.

Suzhou Genhouse Bio Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer and more.

Scripps Research Institute has described nucleoside analogues acting as prodrugs reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Sortina Pharma AB has divulged sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of cancer, Alzheimer's disease and Parkinson's disease.

Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has identified Pim kinase inhibitors reported to be useful for the treatment of cancer.

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have synthesized annulated 2-amino-3-cyano thiophenes and derivatives acting as KRAS GTPase and its mutant inhibitors reported to be useful for the treatment of cancer.

Researchers at Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer and more.

Researchers at Boehringer Ingelheim (BI) Pharma GmbH & Co. KG and Vanderbilt University have described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moieties covalently linked to GTPase KRAS (mutant) binding moieties through a linker.